The treatment has been linked to seven deaths, largely due to heart or respiratory problems. It has also been associated with over 100 serious adverse events in Prader-Willi patients, raising safety and sales concerns.
August 12, 2026 02:48 PM EDT
Four questions on new safety warnings for Neurocrine’s Vykat XR
A group of experts on Prader-Willi syndrome has sounded the alarm on side effects and deaths that may be connected to Neurocrine Biosciences’ medicine Vykat …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
7 deaths and over 100 serious adverse events reported to FDA after treatment with Vykat XR
Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.
A joint statement issued by three organizations warned healthcare professionals about potential safety risks for patients…
A newly approved drug for Prader-Willi syndrome, a rare disease that causes an insatiable desire to eat, may be tied to a series…
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions…
News and commentary from the world of neurology and neuroscience
